Compound Profile

Fucoxanthin

Fucoxanthin carries a Grade C rating — limited evidence.

Use extra caution Generally well tolerated; limited long term safety data. Details

Last reviewed: 1 source citedReport a correctionProfile-wide ·C Limited
Fucoxanthin monograph visual
Generated profile category visual

At a glance

From this profile's structured data
Evidence
Grade C
Safety
Generally well tolerated; limited long-term safety data.
Profile context
UCP1, fat oxidation
Next steps

Continue reading

Quick stats

Evidence level
Limited evidence
Typical onset
Varies by prep
Safety rating
Use extra caution: Generally well tolerated
Best for
UCP1, Fat Oxidation
Avoid / review if
May Interact With Diabetes Medication And Potentiate Hypoglycemia.

Safety

Safety & Cautions

Generally well tolerated; limited long term safety data.

High caution

Caution level: High. Multiple caution categories apply, or the record uses avoid/contraindication language.

  • Interaction-AwareMedication or interaction context is explicitly noted.
  • Anticoagulant CautionBleeding or anticoagulant-adjacent caution language is present.
  • Pregnancy/Breastfeeding CautionPregnancy or breastfeeding caution language is present.

Evidence-based safety

Caution when combined

Severity and certainty are shown separately. A high-priority caution can still be theoretical: these pairings are screened from shared contraindication mechanisms and are not automatically documented clinical interactions. Provenance identifies the source fields that produced each flag; it does not upgrade the certainty of the pairwise claim.

High-Priority Caution

147 flagged pairings

Bleeding / anticoagulant risk

Moderate Caution

110 flagged pairings

Blood-sugar lowering

Evidence Summary

Profile-wide ·C Limited

Evidence lens

Read as directional context, not settled clinical proof.

LimitedLimited evidence

Human clinical evidence: Present in source signals

Mechanistic / preclinical: Mechanism mappedMetabolic Regulation · Glucose Metabolism Support · Glucose Metabolism

Research maturity: Emerging researchmain contexts: UCP1 · Fat Oxidation

Safety boundary: Safety note availableGenerally well tolerated; limited long term safety data.

This profile cites 1 human study.

Evidence Strength

Confidence estimate based on the design quality and consistency of published clinical trials.

Limited evidence

Fucoxanthin has a limited evidence rating.

General wellnessGeneral wellness
Citation density
0.5
Sources
1
Effects
2
Research recency
Mixed recency
Evidence Grade

Grade C: Limited Evidence

Evaluation of methodological rigor, population reach, and evidence alignment.

Design Match
Randomized controlled trial
Risk of Bias
Low
Consistency
Not assessed
Strongest recorded design is a randomized controlled trial, drawn from 2 recorded studies, 2 in people.
How evidence grades work

Each grade reflects the strength and consistency of published human evidence — not marketing claims. Grades are based on study count, design quality, effect size, consistency, and recency.

Strong
Multiple RCTs, consistent direction, adequate effect size
Moderate
Some RCTs or consistent observational data in humans
Preliminary / Mixed
Animal or in-vitro only, or conflicting human data
Traditional / Theoretical
Traditional use only; no controlled human trials
Clinical Study Summaries (1)1 human evidence source · 1 human trial · ~28 participants across 1 human evidence source with reported N · Consistency not yet classifiable

What the evidence actually shows

This table contains 1 structured source, including 1 human evidence source; 1 is a human trial. Across 1 human evidence source with a reported sample size, the approximate participant total is 28; overlapping publications may include some of the same people. Source-to-conclusion relationships are not classified in this structured set, so consistency is not yet classifiable.

Profile-wide evidence grade: see the profile grade above · Confidence: not separately assigned

What would change our conclusion?

Larger, well-controlled human trials using comparable populations, doses, preparations, and clinically meaningful outcomes could materially strengthen or weaken this conclusion. Replication in a different population or a high-quality synthesis resolving current disagreement could also materially change confidence.

StudyDesignNDoseDurationPopulationOutcomeResult & magnitudeSource

Effect of Fucoxanthin on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion

PubMed · J Med Food · 2023

Background
Randomized controlled trial

Randomly assigns participants to interventions or controls, reducing many sources of bias when the trial is conducted well.

n=28PubMed

How Fucoxanthin Works

Simplified mechanism pathway based on preclinical and pharmacological evidence. Does not confirm clinical efficacy.

Mechanism Pathway — How Fucoxanthin Works

How Fucoxanthin WorksFucoxanthin acts on biological target pathways via metabolic (regulation), leading to ucp1.FucoxanthinBiological TargetBiological pathwayMetabolicRegulationUcp1Observable outcomeGlucoseRegulation
CompoundTarget / ReceptorMechanismEffect / Outcome

Dosing

Common form
standardized extract
No standardized dose
Our source data records the usual product form for this ingredient but no studied dose. Preparations differ widely, so follow the standardization on the product you actually have and speak to a clinician before starting.
Mechanisms & biological pathways

Preclinical mechanism details from scientific profiles; these represent plausible pathways but do not guarantee clinical efficacy in humans.

  • Metabolic Regulation
  • Glucose Metabolism Support
  • Glucose Metabolism

Guides that use Fucoxanthin

Continue exploring

Related research paths

Compare & Sourcing

Compare side-by-side tradeoffs or verify active marker guidelines.

Review available sources for Fucoxanthin

Independent database mapping — evaluated separately from safety and efficacy scores.

Check sourcing options

Affiliate disclosure: Shopping links may earn this site a commission at no cost to you. Links are chosen on quality and availability, never commission tiers; safety warnings and evidence ratings stay independent.

Herbs for similar conditions

Tradeoffs

Free safety checklist

Get the Fucoxanthin evidence notes

Occasional research updates, safety context, and product-quality checks for supplement decisions.

We use your email to send the checklist and occasional evidence-first supplement updates. Unsubscribe anytime. Privacy policy.

Safety first · Harm reduction

This information is educational and not medical advice. Start low, avoid risky combinations, and consult a licensed clinician before making health decisions—especially if you use medications, have diagnosed conditions, or are pregnant/breastfeeding.

Learn how we evaluate confidence, safety, and intensity on the methodology page.

Editorial Review

Checked against primary sources, cited evidence, and contraindication language before publication. Evidence claims, safety language, and affiliate modules are reviewed independently. Not personal medical advice.

Editorial Standards →

Help improve this profile

Was this useful for your research?

These controls record only the page and the structured choice you make when analytics consent is enabled. Please don’t include personal medical information in research requests.

Was this evidence summary clear?

Did you find what you were researching?

Compound profile context

How to interpret Fucoxanthin

Fucoxanthin compound profile with evidence context, key research topics, source notes, safety context, and references presented in an evidence-first… Use this compound profile to understand mechanism, evidence quality, and practical safety context before comparing products or building a stack. A biochemical pathway connection can be useful for discovery, but it is not the same as proven benefit in humans.

When reviewing Fucoxanthin, separate the active molecule from the product category around it. Dose form, absorption, extract standardization, medication interactions, and individual sensitivity can change the real-world risk-benefit picture.

For supplement planning, avoid combining multiple compounds with overlapping sedating, stimulating, serotonergic, blood-pressure, anticoagulant, or liver-metabolism effects unless a qualified clinician has reviewed the context.